An AI-based diagnostic system reveals cancerous tissue that may not otherwise be visible during brain tumor surgery. This enables neurosurgeons to remove it while the patient is still under anesthesia – or treat it afterwards with targeted therapies. 

Hematology researchers from Sylvester Comprehensive Cancer Center and the Miller School of Medicine at the University of Miami are authors or co-authors on more than 70 posters to be presented at the Annual Meeting & Exposition of the American Society of Hematology in San Diego, Dec. 7-10. Links to each abstract are included in this tip sheet.

Regular, self-reported symptom screening was associated with reduced symptom burden when compared with usual care for pediatric patients with cancer, according to new research led by scientists at the University of Toronto and The Hospital for Sick Children (SickKids).

The University of Texas Health Science Center at San Antonio dedicated its new $472 million Multispecialty and Research Hospital, the only facility of its kind in South Texas where patients will have access to top specialists and pioneering therapies, especially in cancer treatment.

After a comprehensive two-year follow-up, researchers at the UCLA Health Jonsson Comprehensive Cancer Center found that MRI-guided stereotactic body radiotherapy (SBRT) for prostate cancer significantly reduced long-term side effects and improved quality of life, particularly in bowel and sexual health, compared to conventional CT-guided treatment.

Many bacterial-linked illnesses, such as inflammatory bowel disease or colorectal cancer, are associated with an overgrowth of gut bacteria thought to be bad actors. But when researchers used a machine learning algorithm to predict the density of microbes—called microbial load, from their gut microbiomes, they found that changes in microbial load, rather than the disease, could be a driver behind the presence of disease-associated microbial species.

CAR-T cells show promise against pediatric diffuse midline gliomas, brain and spinal cord tumors that are among the deadliest cancers, a Stanford Medicine trial found.

Researchers have developed an AI powered model that — in 10 seconds — can determine during surgery if any part of a cancerous brain tumor that could be removed remains, a study published in Nature suggests. The technology, called FastGlioma, outperformed conventional methods for identifying what remains of a tumor by a wide margin. Researchers say it has the potential to change the field of neurosurgery by immediately improving comprehensive management of patients with diffuse gliomas.